News
Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...
We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to ...
Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...
But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...
1d
Zacks Investment Research on MSNShould Value Investors Buy Pfizer (PFE) Stock?While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...
5d
24/7 Wall St. on MSNPfizer (NYSE:PFE) Hasn’t Been This Cheap in 13 Years. Time to Buy?Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...
Pfizer’s recent earnings look solid at first glance, but there’s a quirky twist. A US$7 billion unusual expense dragged down ...
Pfizer has received a “Moderate Buy” consensus from fifteen analysts, signaling cautious optimism rather than fanfare. One ...
Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...
Pfizer Inc. closed 29.36% short of its 52-week high of $31.54, which the company reached on July 30th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results